Skip to main content
. Author manuscript; available in PMC: 2013 Jan 11.
Published in final edited form as: Adv Pharmacol. 2012;64:27–81. doi: 10.1016/B978-0-12-394816-8.00002-7

TABLE I.

Overview of Studies Reporting PiB-PET Autopsy Cases

Reference a PiB (+/−) b Clinical diagnosis (at time of PET scan) Cognitive score (at time of PET scan) PET-to-death interval (months) c Cerebral amyloid angiopathy (severity) c Cortical NP frequency c Cortical DP frequency (load) d CERAD/ NIA-RI diagnosis of AD Braak stage for NFT
[1] + DLB CDR = 1/MMSE = 25 3 Severe Sparse Frequent Possible/IL IV
[2] + AD MMSE = 1 10 Sparse Frequent Frequent Definite/HL VI
[3] − Normal CDR = 0 30 Mild Sparse Focally frequent Possible/LL III
[4] − CJD n/s <1 present (n/s) None None n/s n/s
[4] − CJD n/s <1 present (n/s) None Sparse n/s n/s
[5] + PDD CDR = 2/MMSE = 23 < 15 Mild Sparse Frequent Possible/LL III
[5] + PDD CDR = 2/MMSE = 11 <15 None Sparse Frequent Possible/LL III
[5] − PDD CDR = 1/MMSE = 24 <15 None None Sparse n/s I
[6] + DLB MMSE = 10 18 Mild Moderate Frequent n/s/LL III
[7] + AD MMSE = 5 35 present (n/s) Frequent Frequent Definite/ HL VI
[8] + Normal CDR = 0 16 present (n/s) Sparse High (>5%) Normal/NO IV
[8] + Dementia CDR = 1 2 present (n/s) Moderate High (>5%) Probable/IL III
[8] − Normal CDR = 0 20 None None Low (<5%) Normal/NO IV
[8] − Normal CDR = 0 28 None Moderate Low (<5%) Possible/NO III
[8] − Normal CDR = 0 28 None Moderate Low (<5%) Possible/NO IV
[8] − MCI CDR = 0.5 13 present (n/s) Moderate Low (<5%) Possible/IL III
[9] − DLB MMSE = 10 17 Moderate Focally frequent Focally frequent eDefinite/LL II
a

PiB positivity (+) is defined by either local cutoffs defined by the authors or by cutoffs in standard use such as a DVR>1.4 (or BP>0.4) or an SUVR>1.5

b

Clinical diagnosis, AD (Alzheimer disease), CJD (Creutzfeldt–Jakob disease), DLB (dementia with Lewy bodies), MCI (mild cognitive impairment), PDD (Parkinson disease dementia). Highest regional values are shown for congophilic amyloid angiopathy and frequencies of neuritic plaques (NP) and diffuse plaques (DP)

c

CERAD = Consortium to establish a registry for Alzheimer’s disease (diagnoses of possible, probable, or definite AD); NIA-RI = The National Institute on Aging and Reagan Institute (LL = low likelihood of AD, IL = intermediate likelihood of AD, HL = high likelihood of AD, NO = not AD)

d

Diagnosis of definite AD was based on a single area of frequent neuritic plaques in the frontal cortex and strict application of the CERAD criteria.

NFT = neurofibrillary tangles

n/s = not specified